Skip to content

Pharminent

cropped-banner_frontpage_2026-07-11-2.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Commercial
  • With oral obesity race underway, all eyes are on Lilly’s Foundayo launch
  • Commercial

With oral obesity race underway, all eyes are on Lilly’s Foundayo launch

BioSpace

Novo Nordisk's oral Wegovy has a few months' head start on Eli Lilly's newly approved pill.

CommercialMetabolic & GLP-1Read full story

pharminent April 10, 2026 (Last updated: April 10, 2026)

BioSpace

Novo Nordisk’s oral Wegovy has a few months’ head start on Eli Lilly’s newly approved pill.

CommercialMetabolic & GLP-1Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Senju launches first-in-class dry eye disease drug in Japan
Next: RFK Jr. rewrites ACIP rules; Gilead, Roche dig into protein degraders

Related Stories

  • Commercial

Wegovy pill launches in UK as first daily oral GLP1 for weight management

pharminent July 6, 2026
  • Commercial

Tryngolza charts blockbuster course after FDA’s hypertriglyceridemia approval

pharminent June 26, 2026
  • Commercial

Lilly launches its LillyDirect sales channel in the UK

pharminent June 25, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.